Patents Assigned to Allergan Sales, Inc.
  • Methods of treatment with compounds having RAR alpha receptor specific or selective activity
    Publication number: 20020077360
    Abstract: Retinoid compounds which act specifically or selectively on RAR&agr; receptor subtypes in preference over RAR&bgr; and RAR&Ggr; receptor subtypes, posses desirable pharmaceutical properties associated with retinoids, and are particularly suitable for treatment of tumors, such as acute monocytic leukemia, cervical carcinoma, myeloma, ovarian carcinomas and head and neck carcinomas, without having one or more undesirable side effects of retinoids, such as inducement of weight loss, mucocutaneous toxicity, skin irritation and teratogenecity.
    Type: Application
    Filed: November 29, 2001
    Publication date: June 20, 2002
    Applicant: Allergan Sales, Inc.
    Inventors: Min Teng, Tien T. Duong, Roshantha A. Chandraratna
  • Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2a antagonists
    Patent number: 6407250
    Abstract: The present invention provides novel compounds represented by the general formula I. wherein m is an integer of from 1 to 3; n is 0 or an integer of from 1 to 4; R is selected from the group consisting of CO2H, CO2 R6, CH2OH, CH2O R6  and CONR3R4; R1 and R2 are independently selected from the group consisting of H, R6, C1-C6 alkenyl, C1-C6 alkynyl, C3-C7 cycloalkyl, C4-C12 alkylcycloalkyl, C6-C10 aryl, C7-C12 alkyl aryl radicals and heteroatom-substituted derivatives thereof, wherein one or more of the hydrogen or carbon atoms in said radicals is replaced with a halogen, nitrogen or sulfur-containing radical; R3 and R4 are selected from the group consisting of H and R6; and X is selected from the group consisting of R6, hydroxy, N(R6)2, CON(R6)2, SR6, sulfoxy, sulfone, halogen, COOR6, NO2, CN and OR6, wherein R6 is C1-C6 alkyl, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: September 14, 2000
    Date of Patent: June 18, 2002
    Assignee: Allergan Sales, Inc.
    Inventors: Robert M. Burk, Yariv Donde, Michael E. Garst
  • Moveable intraocular lens
    Patent number: 6406494
    Abstract: Intraocular lenses include an optic adapted to focus light toward a retina of an eye and a movement assembly coupled to the optic. In one embodiment, the optic has a far vision correction power and the movement assembly is adapted to cooperate with the eye to effect accommodating movement of the optic, preferably upon radial compression by a capsular bag of the eye. The optic preferably vaults anteriorly relative to the movement assembly. The movement assembly preferably circumscribes the optic and includes a member having a proximal end portion coupled to the optic and a distal end portion extending away from the optic and adapted to contact a capsular bag of the eye.
    Type: Grant
    Filed: March 22, 2000
    Date of Patent: June 18, 2002
    Assignee: Allergan Sales, Inc.
    Inventors: Stephen W. Laguette, Alan J. Lang, Robert E. Glick
  • Compositions containing therapeutically active components having enhanced solubility
    Publication number: 20020071874
    Abstract: Compositions which include therapeutically active components, solubility enhancing components other than cyclodextrins, and oxy-chloro components, wherein the oxy-chloro components are substantially effective as preservatives. In one embodiment, the oxy-chloro components are useful for preserving the therapeutically active components. In one embodiment, the oxy-chloro components include chlorite components. In a useful embodiment, the solubility enhancing components include carboxymethylcellulose.
    Type: Application
    Filed: July 10, 2001
    Publication date: June 13, 2002
    Applicant: Allergan Sales, Inc.
    Inventors: Orest Olejnik, Edward D.S. Kerslake
  • Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents
    Patent number: 6403649
    Abstract: The present invention provides cydopentane heptanoic acid, 2-cycloalkyl or arylalkyl compounds, which may be substituted in the 1-position with amino, amido, ether or ester groups, e.g., a 1-OH cydopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compound. The cydopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compounds of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma. Moreover, the cydopentane heptanoic, 2-(cycloalkyl or arylalkyl) compounds of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; smooth muscle relaxants with application in gastrointestinal disease, reproduction, fertility, incontinence, shock, etc.
    Type: Grant
    Filed: March 6, 2000
    Date of Patent: June 11, 2002
    Assignee: Allergan Sales, Inc.
    Inventors: David F. Woodward, Steven W. Andrews, Robert M. Burk, Michael E. Garst
  • 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
    Patent number: 6403638
    Abstract: Compounds having the formulas below, where R is H, lower alkyl, or a pharmaceutically acceptable salt, and where R1 represents i-propyl, t-butyl or n-butyl groups, have selective RXR retionoid agonist activity.
    Type: Grant
    Filed: March 21, 2000
    Date of Patent: June 11, 2002
    Assignee: Allergan Sales, Inc.
    Inventors: Vidyasagar Vuligonda, Kwok Yin Tsang, Jayasree Vasudevan, Roshantha A. Chandraratna
  • Clostridial toxin derivatives and methods for treating pain
    Publication number: 20020068699
    Abstract: Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative thereof, attached to a targeting moiety, wherein the targeting moiety is selected from a group consisting of transmission compounds which can be released from neurons upon the transmission of pain signals by the neurons, and compounds substantially similar to the transmission compounds.
    Type: Application
    Filed: August 23, 2001
    Publication date: June 6, 2002
    Applicant: Allergan Sales, Inc.
    Inventor: Stephen Donovan
  • Methods of treating animals with botulinum toxin pharmaceutical compositions
    Publication number: 20020064536
    Abstract: Methods for treating mammals with botulinum toxin comprise administering at least one type of botulinum toxin to the mammal. The botulinum toxin may be administered in a composition having a polysacharide that stabilizes the botulinum toxin. The compositions administered to the mammals have reduced immunogenicity, and are preferably non-immunogenic. The methods may also be practiced with recombinant, or species-specific, serum albumins.
    Type: Application
    Filed: January 14, 2002
    Publication date: May 30, 2002
    Applicant: Allergan Sales, Inc.
    Inventor: Terrence J. Hunt
  • Nucleic acid encoding a human EP prostaglandin receptor
    Patent number: 6395878
    Abstract: A gene encoding the HP4 human prostaglandin receptor is disclosed. The protein encoded by this gene exhibits significant sequence identity with other prostaglandin receptors. The HP4 receptor, when expressed in eukaryotic cells, is capable of binding prostaglandins and their analogs and stimulating adenylate cyclase activity in response to prostaglandins. Also disclosed are antisense agents able to decrease or prevent translation of a human HP4 prostaglandin receptor.
    Type: Grant
    Filed: March 12, 1999
    Date of Patent: May 28, 2002
    Assignee: Allergan Sales, Inc.
    Inventors: John W. Regan, Daniel W. Gil, David F. Woodward
  • Power mode phaco
    Patent number: 6394974
    Abstract: Phacoemulsification apparatus includes a phacoemulsification handpiece having a needle and an electrical system for ultrasonically vibrating said needle along with a power source for providing electrical power to the handpiece electrical system. Irrigation fluid is provided to the handpiece needle and aspirating fluid is removed from the handpiece needle. A determination of a voltage current phase relationship of the provided electrical power is made and in response thereto a control system varies a power level duty cycle provided to the handpiece electrical system from the power source and/or modify the aspiration flow rate.
    Type: Grant
    Filed: April 23, 1999
    Date of Patent: May 28, 2002
    Assignee: Allergan Sales, Inc.
    Inventors: Kenneth E. Kadziauskas, James W. Staggs
  • Ocular hypotensive lipids
    Patent number: 6395787
    Abstract: Compounds of Formula 1, where the symbols are as defined in the specification, are useful as ocular hypotensive agents but do not exert their activity through the FP prostaglandin receptor. In particular the compound PGF2&agr; 1-ethanolamide, having the formula was discovered to be present in mammalian tissue as a naturally occurring substance, was synthesized in a substantially pure form and was found to be effective for lowering intraocular pressure in the mammalian eye, but not acting through the FP receptor through which many ocular hypotensive prostaglandins act.
    Type: Grant
    Filed: February 8, 2000
    Date of Patent: May 28, 2002
    Assignee: Allergan Sales, Inc.
    Inventors: David F. Woodward, Helen H. Usansky, Steven W. Andrews, Robert M. Burk, June Chen, Achim H-P. Krauss, Cherukury Madhu
  • CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-THIOCARBAMOYLOXY AND 2-CARBAMOYLOXY COMPOUNDS AS THERAPEUTIC AGENTS
    Publication number: 20020058692
    Abstract: The invention relates to the use of cyclopentane heptan(ene)oic acid, 2-thiocarbamoyloxy and carbamoyloxy as therapeutic agents e.g. as ocular hypotensives.
    Type: Application
    Filed: June 6, 2001
    Publication date: May 16, 2002
    Applicant: ALLERGAN SALES, INC.
    Inventor: Robert M. Burk
  • Methods and compositions for modulating alpha adrenergic receptor activity
    Publication number: 20020058839
    Abstract: Methods and compositions for the treatment of pain. Particularly disclosed are new compositions for the treatment of chronic pain, and methods for their use.
    Type: Application
    Filed: February 5, 2001
    Publication date: May 16, 2002
    Applicant: ALLERGAN SALES, INC.
    Inventors: Ken Chow, Daniel W. Gil, Wenkui Fang, Michael E. Garst, Larry A. Wheeler
  • Treatment of tumors with RAR&agr; selective retinoid compounds in combination with other anti-tumor agents
    Patent number: 6387950
    Abstract: Compounds which are specific or selective agonists of RAR&agr; receptors in preference over RAR&bgr; and RAR&ggr; receptors, and particularly compounds of the formula where R is a H, lower alkyl of 1 to 6 carbons, or a pharmaceutically acceptable salt, are useful for treating a malignant disease or condition in a mammal. In treatment of solid tumors the compound exhibit synergistic anti-proliferative effect with human recombinant interferon.
    Type: Grant
    Filed: April 2, 2001
    Date of Patent: May 14, 2002
    Assignee: Allergan Sales, Inc.
    Inventors: Alissar Nehme, Richard L. Beard, Roshantha A. Chandraratna
  • Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
    Patent number: 6387892
    Abstract: Novel compounds having the Formulas 1 through 8, wherein the symbols have the meaning defined in the specification, and certain previously known compounds have been discovered to act as inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids. The compound can also be used in co-treatment with retinoids.
    Type: Grant
    Filed: June 7, 2001
    Date of Patent: May 14, 2002
    Assignee: Allergan Sales, Inc.
    Inventors: Jayasree Vasudevan, Alan T. Johnson, Liming Wang, Dehua Huang, Roshantha A. Chandraratna
  • Compounds having activity as inhibitors of cytochrome P450RAI
    Patent number: 6387951
    Abstract: Compounds having Formulas 5 and 6 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids.
    Type: Grant
    Filed: August 29, 2000
    Date of Patent: May 14, 2002
    Assignee: Allergan Sales, Inc.
    Inventors: Jayasree Vasudevan, Alan T. Johnson, Liming Wang, Dehua Huang, Roshantha A. Chandraratna
  • Benzofuran, indole or benzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
    Patent number: 6388105
    Abstract: Compounds of the formula Where the variables are defined as in the specification, are selective agonists of RXR retinoid receptors.
    Type: Grant
    Filed: September 27, 2001
    Date of Patent: May 14, 2002
    Assignee: Allergan Sales, Inc.
    Inventors: Vidyasagar Vuligonda, Roshantha A. Chandraratna
  • Biodegradable neurotoxin implant
    Patent number: 6383509
    Abstract: A biocompatible implant for continuous in vivo release of a neurotoxin over a treatment period extending from one month to five years. The implant can be made of casting a solution of a polymer, such as an ethyl vinyl acetate copolymer and the neurotoxin. The neurotoxin can be a botulinum toxin.
    Type: Grant
    Filed: August 7, 2001
    Date of Patent: May 7, 2002
    Assignee: Allergan Sales, Inc.
    Inventors: Stephen Donovan, Daniel G. Brady
  • Calcium blockers to treat proliferative vitreoretinopathy
    Patent number: 6380261
    Abstract: Glutamate causes migration and proliferation of retinal pigment epithelium and/or glial cells, and glutamate antagonists can prevent, treat or reduce retinal pigment epithelium and/or glial migration and the subsequent development of proliferative vitreoretinopathy. Avoidance or management of proliferative vitreoretinopathy can be achieved by administering to the patient a compound capable of reducing glutamate-induced retinal cell migration in a concentration effective to reduce such migration.
    Type: Grant
    Filed: December 13, 1999
    Date of Patent: April 30, 2002
    Assignee: Allergan Sales, Inc.
    Inventor: Evan B. Dreyer
  • Cyclopentane heptan(ENE)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents
    Patent number: 6380250
    Abstract: The invention relates to the use of cyclopentane heptan(ene)oic acid, 2-thiocarbamoyloxy and carbamoyloxy as therapeutic agents e.g. as ocular hypotensives.
    Type: Grant
    Filed: June 6, 2001
    Date of Patent: April 30, 2002
    Assignee: Allergan Sales, Inc.
    Inventor: Robert M. Burk